Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Federal Circuit reverses and remands 2008 Mirapex patent validity opinion

This article was originally published in Scrip

Executive Summary

A federal appeals court has handed a win to Boehringer Ingelheim in a patent infringement case, and has reversed and remanded a 2008 ruling from a lower court that invalidated a US patent related to the company's Parkinson's disease treatment, Mirapex (pramipexole dihydrochloride), for obviousness-type double patenting.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts